Phase III analysis of Xtampza ER (oxycodone extended-release capsules) for chronic pain published in Current Medical Research and Opinion- Collegium Pharmaceutical
Collegium Pharmaceutical has announced the publication of an analysis of the duration of effect of Xtampza ER (oxycodone extended-release capsules) administered every 12 hours during the Double-blind Maintenance Phase of a multicenter, 12-week clinical study. The publication is titled, “Evaluation of the Durability of Pain Relief Throughout a 12-Hour Dosing Interval of a Novel, Extended-Release, Abuse-Deterrent Formulation of Oxycodone – Oxycodone DETERx” and is published in Current Medical Research and Opinion.
The analysis of the data from the Phase 3 randomized withdrawal, double-blind, placebo-controlled, enriched-enrollment, parallel-group, multicenter, 12-week clinical study in patients with chronic low back pain showed limited use of acetaminophen, the only rescue medication used in the study. In addition, the analysis showed no increase in rescue medication consumption from 8 to 12 hours after dosing, which is the time interval commonly associated with end-of-dose failure leading to inadequate analgesic effect; these data suggest that subjects maintained pain relief over the entire dosing interval with twice daily administration of Xtampza ER.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)